J-1048 (an ALK5 inhibitor, another name for a TGF-βR I inhibitor) reduces the phosphorylation levels of TGF-βR I and Smad2/3 and increases Smad7 expression in a dose-dependent manner, thereby regulating TGF-β signal transduction and inhibiting thioacetamide-induced liver fibrosis in mice (88). This evidence concerns the gene TGFB1 and Hepatic fibrosis.